种植体周炎的重建性手术治疗:一项多中心随机对照临床试验
这项多中心随机对照试验纳入138例患者共147枚种植体周炎种植体,随机分为对照组(翻瓣清创术)和试验组(使用骨替代材料的重建性手术),评估12个月时复合结局。结果显示两组仅约16.4%和13.5%的种植体达到全部复合标准,骨替代材料未改善探诊深度和出血的减少,但试验组颊侧黏膜退缩较轻。
要点
- 两组12个月复合结局达标率分别为试验组16.4%和对照组13.5%。
- 两组探诊深度减少3.7 mm、边缘骨水平获得约1.0 mm。
- 试验组颊侧黏膜退缩(均值0.7 mm)轻于对照组(均值1.1 mm)。
核心结论
- 种植体周炎手术治疗在12个月时有效改善临床和影像学状态。
- 使用骨替代材料未改善探诊深度和出血的减少,但试验组颊侧黏膜退缩较轻。
- 两组患者满意度均高。
研究设计与样本
- 多中心随机对照临床试验,138例患者共147枚种植体周炎种植体。
- 通过掷硬币随机分为对照组(翻瓣清创术)和试验组(使用骨替代材料的重建性手术)。
- 未对分组实施盲法。
- 主要结局为12个月复合指标:种植体未脱落、所有位点无探诊出血/溢脓、所有位点探诊深度≤5 mm、种植体颊侧黏膜边缘退缩≤1 mm。
主要发现
- 随访期间4枚种植体(试验组1枚、对照组3枚)因疾病进展被移除。
- 12个月时检查试验组69枚、对照组68枚种植体。
- 试验组16.4%和对照组13.5%的种植体达到全部预设复合结局标准。
- 两组探诊深度减少均为3.7 mm,边缘骨水平获得均约1.0 mm。
- 平均探诊出血百分比降低在试验组为45%、对照组为50%,组间无显著差异。
关键数值与推荐
- 12个月复合结局达标率:试验组16.4% vs 对照组13.5%。
- 探诊深度减少:试验组3.7 mm vs 对照组3.7 mm。
- 边缘骨水平获得:试验组约1.0 mm vs 对照组约1.0 mm。
- 平均探诊出血百分比降低:试验组45% vs 对照组50%,组间无显著差异。
- 颊侧黏膜退缩:试验组均值0.7 mm(标准差0.9 mm)vs 对照组均值1.1 mm(标准差1.5 mm)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未对分组实施盲法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the potential benefit of the use of a bone substitute material in the reconstructive surgical therapy of peri-implantitis. METHODS: In this multicenter randomized clinical trial, 138 patients (147 implants) with peri-implantitis were treated surgically, randomized by coin toss to either a control (access flap surgery) or a test group (reconstructive surgery using bone substitute material). Clinical assessments, including probing pocket depth (PPD), bleeding and suppuration on probing (BOP & SOP) as well as soft tissue recession (REC), were recorded at baseline, 6 and 12 months. Marginal bone levels (MBL), measured on intra-oral radiographs, and patient-reported outcomes (PROs) were recorded at baseline and 12 months. No blinding to group allocation was performed. The primary outcome at 12 months was a composite measure including (i) implant not lost, (ii) absence of BOP/SOP at all aspects, (iii) PPD ≤5 mm at all aspects and (iv) ≤1 mm recession of mucosal margin on the buccal aspect of the implant. Secondary outcomes included (i) changes of MBL, (ii) changes of PPD, BOP%, and buccal KM, (iii) buccal REC and (iv) patient-reported outcomes. RESULTS: During follow-up, four implants (one in the test group, three in the control group) in four patients were removed due to disease progression. At 12 months, a total of 69 implants in the test and 68 implants in the control group were examined. Thus, 16.4% and 13.5% of implants in the test and control group, respectively, met all predefined criteria of the composite outcome. PPD reduction and MBL gain were 3.7 mm and about 1.0 mm in both groups. Reduction in mean BOP% varied between 45% (test) and 50% (control), without significant differences between groups. Buccal REC was less pronounced in the test group (M = 0.7, SD = 0.9 mm) when compared to controls (M = 1.1, SD = 1.5 mm). PROs were favorable in both groups without significant differences. One case of allergic reaction to the antibiotic therapy was recorded. No other adverse events were noted. CONCLUSIONS: Surgical therapy of peri-implantitis effectively improved the clinical and radiographic status at 12 months. While the use of a bone substitute material did not improve reductions of PPD and BOP, buccal REC was less pronounced in the test group. Patient satisfaction was high in both groups.
引用
- Derks J, Ortiz-Vigón A, Guerrero A, et al. Reconstructive surgical therapy of peri-implantitis: A multicenter randomized controlled clinical trial. Clin Oral Implants Res. 2022. PMID: 35804491. doi:10.1111/clr.13972
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。